Research programme: glucagon-like peptide-1 agonists - i2O Therapeutics
Alternative Names: GLP1 analogs - i2O TherapeuticsLatest Information Update: 13 Sep 2024
At a glance
- Originator i2O Therapeutics
- Class Antihypoglycaemics; Glucagon-like peptides; Peptide hormones
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus